Article Per Year (5 Year)
p-Index From 2020 - 2025
2.083
P-Index
This Author published in this journals
All Journal Indonesian Journal of Cancer Chemoprevention Indonesian Journal of Cancer JFIOnline Jurnal Ilmu Kefarmasian Indonesia Journal of Stem Cell Research and Tissue Engineering Cermin Dunia Kedokteran Indonesian Journal of Cancer eJournal Kedokteran Indonesia Makara Journal of Health Research Jurnal Penyakit Dalam Indonesia
Cosphiadi Irawan
Divisi Hematologi Onkologi Medik, Departemen Ilmu Penyakit Dalam, RSUPN Dr. Cipto Mangunkusumo, Fakultas Kedokteran Universitas Indonesia, Jakarta, Indonesia
Biochemistry, Genetics & Molecular Biology Engineering Health Professions Immunology & microbiology Medicine & Pharmacology Neuroscience Public Health Veterinary

Published : 19 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 19 Documents
Search

 1   2 
Non-Hodgkin’s Lymphoma in Jakarta Reksodiputro, Harryanto; Irawan, Cosphiadi; Hardjolukito, Endang
Indonesian Journal of Cancer Vol 5, No 3 (2011): Jul - Sep 2011
Publisher : "Dharmais" Cancer Center Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (75.379 KB)

Abstract

Tujuan: Melihat karakteristik pasien Limfoma Non Hodgkin di Jakarta. Metode: studi retrospektif. Sampel adalah pasien Limfoma Non Hodgkin yang berobat di RS Cipto Mangunkusumo dan RSK “Dharmais” antara tahun 2004-2005.Hasil: Tujuh puluh delapan persen pasien memiliki usia kurang dari 60 tahun dengan gambaran mayoritas jenis kelamin laki-laki, stadium awal (60,8%) dan status performans yang baik (ECOG 0-1; 86,67%). Berdasarkan evaluasi terhadap paparan, didapati delapan puluh persen pasien tidak diketahui paparannya.Dari 153 pasien, 94 pasien diobati dengan kemoterapi regimen CHOP, namun hanya 51 pasien yang menyelesaikan minimal 6 siklus kemoterapi. Dilaporkan juga respon terhadap terapi adalah: remisi komplit (52,38%), remisi parsial (26,19%) dan respon minimal (14,2%).Pada kelompok pasien yang diobati dengan regimen kemoterapi CHOP, dilaporkan bahwa delapan puluh persen pasien berusia di bawah 60 tahun, memiliki stadium awal (stadium I-II; 74,47%) dan status performmans yang baik (ECOG I-II; 93,3%). Juga dilaporkan bahwa sembilan puluh persen pasien memiliki ? 1 keterlibatan ekstranodal dan kadar LDH normal (60%). Berdasarkan hasil patologi, dilaporkan lima puluh persen pasien memiliki gambaran patologi DLBCL (Diffuse Large B Cell L).Kesimpulan: Sebagian besar pasien Limfoma Non Hodgkin di Jakarta memiliki karakteristik klinis: usia di bawah 60 tahun dengan jenis kelamin laki-laki, stadium awal dan status performans yang baik. Pada kelompok pasien yang menjalani kemoterapi regimen CHOP juga dilaporkan karakteristik klinis yang sama. Lima puluh persen pasien yang menjalani kemoterapi regimen CHOP mencapai respon komplit setelah menjalani minimal 6 siklus kemoterapi.Katakunci: Limfoma Non Hodgkin, Performa studi, remisi
Survei Pengetahuan Dokter Spesialis terhadap Penggunaan Opiat pada Tatalaksana Nyeri Kanker di Rumah Sakit Pemerintah, Jakarta, 2017 INDRAYANI, LENNY; SETIABUDY, RIANTO; SOETIKNO, VIVIAN; IRAWAN, COSPHIADY
Indonesian Journal of Cancer Vol 11, No 4 (2017): October- December 2017
Publisher : Indonesian Journal of Cancer

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (1097.236 KB)

Abstract

Treatment of cancer pain often requires opioids, and morphine is a gold standard in the management of severe cancer pain. Inadequate knowledge of cancer pain management causes opioid usage is not optimal. Indonesia is one of the countries with very low opioid consumption. The purpose of this study was to find out the physician’s knowledge about the management of cancer pain in choosing opioid, administration, doses, side effects, addiction and factors of opioid that barrier in pain management. This cross-sectional study was conducted in General Hospital Jakarta and a Private Hospital in Tangerang. Inclusion criteria were medical specialist who treating cancer pain. This study used questionnaires that filled out by respondents and confidential. Score of adequate knowledge was ≥ 70, and to assess the relationship between knowledge of opioid use with specialization analyzed by Chi-square test and Fisher’s exact if Chi-square requirement is not fulfilled. Statistical analysis was performed by SPSS version 20. From a total of 146 distributed questionnaires, we received 103 questionnaires (70,5%). In this study, the majority of respondents (69,9%) had inadequate knowledge. The highest rate (70,55) was found in the choosing opioid section, while the lowest rate (49,5) was found in the opioid side effects section. There is no significant relationship between physician knowledge on opioid usage and specialization (P= 0,355). Government regulation is major obstacle to opioid use, followed by lack of training, drug availability and knowledge of side effects ABSTRAK Penatalaksanaan nyeri kanker sering kali membutuhkan opiat dengan morfin sebagai gold standard menurut panduan WHO analgesic step ladder . Pengetahuan penalaksanaan nyeri kanker yang kurang menyebabkan penggunaan opiat yang tidak optimal. Indonesia merupakan salah satu negara dengan konsumsi opiat yang sangat rendah. Tujuan studi ini adalah untuk mengetahui pengetahuan dokter mengenai penanganan nyeri kanker dalam pemilihan opiat, cara pemberian, dosis, efek samping, dan adanya adiksi, serta faktor-faktor yang menjadi penghambat pada penanganan nyeri kanker. Desain penelitian ini merupakan survei potong lintang ( cross sectional ) yang dilakukan terhadap dokter spesialis yang menangani nyeri kanker di Rumah Sakit Umum Pemerintah Jakarta dan salah satu rumah sakit swasta di Tangerang. Penelitian ini menggunakan kuesioner yang diisi responden dan bersifat rahasia. Pengetahuan dianggap baik bila nilai ≥ 70. Sedangkan untuk menilai hubungan antara pengetahuan tentang penggunaan opiat dengan bidang spesialisasi dokter dianalisis dengan uji Chi-square . Hasil statistik dianalisis dengan menggunakan SPSS versi 20. Dari total 146 kuesioner yang didistribusikan, didapatkan 103 kuesioner (70,5%) yang direspons. Pada penelitian ini, mayoritas responden (69,9%) mempunyai pengetahuan yang tidak adekuat. Rerata tertinggi didapatkan pada bagian pemilihan opiat 70,55; sedangkan rerata terendah didapatkan pada bagian efek samping opiat, yaitu 47,56. Tidak terdapat hubungan bermakna antara pengetahuan dokter tentang penggunaan opiat dengan bidang spesialisasi (P= KORESPONDENSI: Lenny Indrayani Departemen Farmakologi dan Terapeutik, Universitas Indonesia. Email: lenny3ma@gmail.com Indonesian Journal of Cancer Vol. 11, No. 4 October - December 2017160 0,355). Regulasi pemerintah merupakan penghambat utama pada penggunaan opiat, disusul dengan kurangnya pelatihan, ketersediaan obat dan pengetahuan tentang efek samping.
UJI SITOTOKSISITAS BUAH MERAH, MAHKOTA DEWA DAN TEMU PUTIH TERHADAP SEL KANKER SERVIKS Radji, Maksum; Aldrat, Hendri; Harahap, Yahdiana; Irawan, Cosphiadi
JFIOnline | Print ISSN 1412-1107 | e-ISSN 2355-696X Vol 5, No 1 (2010)
Publisher : Indonesian Research Gateway

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

The cytotoxic effect of herbal medicines has been examined using HeLa cells line (cervical cancer cell culture). The result showed that the LC50 value of buah merah [Pandanus conoideus Lam.], mahkota dewa [Phaleria macrocarpa (Scheff.) Boerl.] and temu putih [Curcuma zedoaria (Berg.) Roscoe] extracts were  421 µg/ml, 835µg/ml and 58,9 µg/ml after 24 hour incubation, whereas the LC50 of each extract were 276.79 µg/ml, 415,9 µg/ml and 29.19 µg/ml after 48 hour incubation respectively. The cytotoxic activity of temu putih [Curcuma zedoaria (Berg.)] extract to HeLa cells was stronger than buah merah [Pandanus conoideus Lam.] and mahkota dewa [Phaleria macrocarpa (Scheff.) Boerl.] extracts.   ABSTRAK Telah dilakukan penelitian efek sitotoksisitas ekstrak buah merah [Pandanus conoideus Lam.], mahkota dewa [Phaleria macrocarpa (Scheff.) Boerl.] and temu putih [Curcuma zedoaria (Berg.) Roscoe] terhadap sel HeLa (kultur sel kanker serviks). Hasil penelitian menunjukkan bahwa nilai LC50 dari ketiga ekstrak tersebut masing-masing adalah 421 µg/ml, 835µg/ml and 58,9 µg/ml, setelah waktu inkubasi selama 24 jam, sedangkan LC50 setelah diinkubasi selama 48 jam adalah  276.79 µg/ml, 415,9 µg/ml and 29.19 µg/ml. Aktivitas sitotoksik  temu putih [Curcuma zedoaria (Berg.)] terhadap sel HeLa  lebih kuat dibandingkan dengan buah merah [Pandanus conoideus Lam.] dan mahkota dewa [Phaleria macrocarpa (Scheff.) Boerl.]
UJI SITOTOKSISITAS BUAH MERAH, MAHKOTA DEWA DAN TEMU PUTIH TERHADAP SEL KANKER SERVIKS Radji, Maksum; Aldrat, Hendri; Harahap, Yahdiana; Irawan, Cosphiadi
Jurnal Farmasi Indonesia Vol 5, No 1 (2010)
Publisher : Jurnal Farmasi Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35617/jfi.v5i1.36

Abstract

The cytotoxic effect of herbal medicines has been examined using HeLa cells line (cervical cancer cell culture). The result showed that the LC50 value of buah merah [Pandanus conoideus Lam.], mahkota dewa [Phaleria macrocarpa (Scheff.) Boerl.] and temu putih [Curcuma zedoaria (Berg.) Roscoe] extracts were  421 µg/ml, 835µg/ml and 58,9 µg/ml after 24 hour incubation, whereas the LC50 of each extract were 276.79 µg/ml, 415,9 µg/ml and 29.19 µg/ml after 48 hour incubation respectively. The cytotoxic activity of temu putih [Curcuma zedoaria (Berg.)] extract to HeLa cells was stronger than buah merah [Pandanus conoideus Lam.] and mahkota dewa [Phaleria macrocarpa (Scheff.) Boerl.] extracts.   ABSTRAK Telah dilakukan penelitian efek sitotoksisitas ekstrak buah merah [Pandanus conoideus Lam.], mahkota dewa [Phaleria macrocarpa (Scheff.) Boerl.] and temu putih [Curcuma zedoaria (Berg.) Roscoe] terhadap sel HeLa (kultur sel kanker serviks). Hasil penelitian menunjukkan bahwa nilai LC50 dari ketiga ekstrak tersebut masing-masing adalah 421 µg/ml, 835µg/ml and 58,9 µg/ml, setelah waktu inkubasi selama 24 jam, sedangkan LC50 setelah diinkubasi selama 48 jam adalah  276.79 µg/ml, 415,9 µg/ml and 29.19 µg/ml. Aktivitas sitotoksik  temu putih [Curcuma zedoaria (Berg.)] terhadap sel HeLa  lebih kuat dibandingkan dengan buah merah [Pandanus conoideus Lam.] dan mahkota dewa [Phaleria macrocarpa (Scheff.) Boerl.]
Peran Metformin sebagai Inhibitor Jaras Insulin-like Growth Factor-1 Receptor (IGF-1R), Epidermal Growth Factor Receptor (EGFR), dan Mammalian Target of Rapamycin (mTOR) pada Kemoterapi Kanker Paru Filbert Jayalie, Vito; William, Andy; -, Shelly; Irawan, Cosphiadi
Cermin Dunia Kedokteran Vol 43, No 6 (2016): Metabolik
Publisher : PT. Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (853.143 KB) | DOI: 10.55175/cdk.v43i6.68

Abstract

Kanker paru adalah salah satu jenis kanker dengan prevalensi dan mortalitas yang tinggi di dunia. Beberapa studi klinis menunjukkan bahwa metformin dapat menurunkan angka mortalitas berbagai jenis kanker, termasuk kanker paru. Metformin dapat menghambat berbagai jaras persinyalan, seperti Insulin-like Growth Factor Receptor (IGF-1R), Epidermal Growth Factor Receptor (EGFR), dan mammalian Target of Rapamycin (mTOR), yang berperan dalam pertumbuhan dan proliferasi sel kanker. Selain itu, metformin juga memiliki efek sinergis dengan kemoterapi standar, yaitu dapat meningkatkan survival rate serta mengurangi dosis kemoterapi. Masih diperlukan penelitian lebih lanjut untuk mengetahui potensi kombinasinya dengan kemoterapi standar pada pengobatan kanker paru.
Penggunaan Obat Herbal pada Pasien Kanker Serviks MAKSUM RADJI; HENDRI ALDRAT; YAHDIANA HARAHAP; COSPHIADI IRAWAN
JURNAL ILMU KEFARMASIAN INDONESIA Vol 8 No 1 (2010): JIFI
Publisher : Fakultas Farmasi Universitas Pancasila

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (1717.125 KB)

Abstract

Herbal medicines have widely been used to treat many type of diseases despite the advance of standard or conventional therapy. In fact, many people in Indonesia use medicinal plant as their customary part of life. Therefore, it is necessary to further explore the use of herbal medicines through modern perception. ln this study we would like to know the frequency and species of herbal medicines used among cervical cancer patients in National Cancer Hospital Dharmais, Jakarta, Indonesia and also to assess the relationship between age, education, jobs, stage of cancer, and payment status of the patients. The results were 61,8% patients used herbal medicines. The herbal medicines used most were mahkota dewa (Phaleria macrocarpa Scheetf Boerl.) 35.3%, temu putih (Curcuma zedoaria Rosc.) 32.4%, and buah merah (Pandanus conoideus Lam) 17,6%. There was a significant relationship (p=0,039) between the use of herbal medicines and stage of cancer but no relationship between age, education, occupation, income and payment status with the use of herbal medicines.
Peran Metformin sebagai Inhibitor Jaras Insulin-like Growth Factor-1 Receptor (IGF-1R), Epidermal Growth Factor Receptor (EGFR), dan Mammalian Target of Rapamycin (mTOR) pada Kemoterapi Kanker Paru Vito Filbert Jayalie; Andy William; Shelly -; Cosphiadi Irawan
Cermin Dunia Kedokteran Vol 43, No 6 (2016): Metabolik
Publisher : PT. Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55175/cdk.v43i6.68

Abstract

Kanker paru adalah salah satu jenis kanker dengan prevalensi dan mortalitas yang tinggi di dunia. Beberapa studi klinis menunjukkan bahwa metformin dapat menurunkan angka mortalitas berbagai jenis kanker, termasuk kanker paru. Metformin dapat menghambat berbagai jaras persinyalan, seperti Insulin-like Growth Factor Receptor (IGF-1R), Epidermal Growth Factor Receptor (EGFR), dan mammalian Target of Rapamycin (mTOR), yang berperan dalam pertumbuhan dan proliferasi sel kanker. Selain itu, metformin juga memiliki efek sinergis dengan kemoterapi standar, yaitu dapat meningkatkan survival rate serta mengurangi dosis kemoterapi. Masih diperlukan penelitian lebih lanjut untuk mengetahui potensi kombinasinya dengan kemoterapi standar pada pengobatan kanker paru.
Non-Hodgkins Lymphoma in Jakarta Harryanto Reksodiputro; Cosphiadi Irawan; Endang Hardjolukito
Indonesian Journal of Cancer Vol 5, No 3 (2011): Jul - Sep 2011
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (75.379 KB) | DOI: 10.33371/ijoc.v5i3.171

Abstract

Tujuan: Melihat karakteristik pasien Limfoma Non Hodgkin di Jakarta. Metode: studi retrospektif. Sampel adalah pasien Limfoma Non Hodgkin yang berobat di RS Cipto Mangunkusumo dan RSK Dharmais antara tahun 2004-2005.Hasil: Tujuh puluh delapan persen pasien memiliki usia kurang dari 60 tahun dengan gambaran mayoritas jenis kelamin laki-laki, stadium awal (60,8%) dan status performans yang baik (ECOG 0-1; 86,67%). Berdasarkan evaluasi terhadap paparan, didapati delapan puluh persen pasien tidak diketahui paparannya.Dari 153 pasien, 94 pasien diobati dengan kemoterapi regimen CHOP, namun hanya 51 pasien yang menyelesaikan minimal 6 siklus kemoterapi. Dilaporkan juga respon terhadap terapi adalah: remisi komplit (52,38%), remisi parsial (26,19%) dan respon minimal (14,2%).Pada kelompok pasien yang diobati dengan regimen kemoterapi CHOP, dilaporkan bahwa delapan puluh persen pasien berusia di bawah 60 tahun, memiliki stadium awal (stadium I-II; 74,47%) dan status performmans yang baik (ECOG I-II; 93,3%). Juga dilaporkan bahwa sembilan puluh persen pasien memiliki ? 1 keterlibatan ekstranodal dan kadar LDH normal (60%). Berdasarkan hasil patologi, dilaporkan lima puluh persen pasien memiliki gambaran patologi DLBCL (Diffuse Large B Cell L).Kesimpulan: Sebagian besar pasien Limfoma Non Hodgkin di Jakarta memiliki karakteristik klinis: usia di bawah 60 tahun dengan jenis kelamin laki-laki, stadium awal dan status performans yang baik. Pada kelompok pasien yang menjalani kemoterapi regimen CHOP juga dilaporkan karakteristik klinis yang sama. Lima puluh persen pasien yang menjalani kemoterapi regimen CHOP mencapai respon komplit setelah menjalani minimal 6 siklus kemoterapi.Katakunci: Limfoma Non Hodgkin, Performa studi, remisi
Cyclin D1 and Chemotherapy Response Rahmat Cahyanur; Cosphiadi Irawan
Indonesian Journal of Cancer Vol 15, No 1 (2021): March
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (222.81 KB) | DOI: 10.33371/ijoc.v15i1.782

Abstract

Cyclin D1 is a protein that plays a role in the transition from the G1 to S phase of the cell cycle. Cyclin D1 expression has been found to increase in various malignancies and, in many studies, was associated with tumor growth, stage, lymph node involvement, distant metastases, and poor prognosis. Until now, studies on the association of cyclin D1 expression level with chemotherapy response have shown different results. An in-depth understanding of the cell cycle will allow doctors to develop target therapies that work when specific interventions are carried out at certain stages. Some studies reported that cyclin D1 expression was inversely related to chemotherapy response, while others showed opposite results. A significant number of studies have attempted to elucidate this ambiguous effect of cyclin D1. The suggested mechanism involves the difference of cancer cell types, the effect of chromosome instability in a few malignancies, trigger to an excessive DNA repair protein expression stimulus, and the response to DNA damage severity. The ambiguous effect of cyclin D1 towards chemotherapy was thought to arise from the difference in tumor type, chemotherapy agents used, and cell damage severity caused by cytostatics as per different research works. More in-depth research with parallel evaluation of other possible mechanisms such as DNA repair should elucidate the reason behind the inconsistent findings.
Value of Heart Rate Variability, Neutrophil-Lymphocyte Ratio and Quality of Life of Patients with Depressive Symptoms in Acute Myocardial Infarction Shatri, Hamzah; Adli, Mizanul; Muhadi, Muhadi; Abdullah, Murdani; Irawan, Cosphiadi; Putranto, Rudi; Koesnoe, Sukamto; Wijaya, Ika Prasetya
Jurnal Penyakit Dalam Indonesia Vol. 9, No. 4
Publisher : UI Scholars Hub

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Introduction. Major depression criteria can be found in more than 20% of coronary heart patients and more than 30% acute coronary syndrome patients have significant depressive symptoms. Several studies have shown that reduction of hearth rate variability (HRV) and enhancement of neutrophil lymphocyte ratio (NLR) can cause enhancement of morbidity and mortality in myocardial infarction patients. On the other hand, depression can cause reduction of HRV, enhancement of NLR and reduction of quality of life. This study aimed to determine differences in HRV, NLR and quality of life between acute myocardial infarction (AMI) patients with depressive symptoms and AMI patients without depressive symptoms. Methods. A cross-sectional study was conducted among AMI patients who were treated during the period of March to July 2021 at the Intensive Cardiac Care Unit (ICCU) Cipto Mangunkusumo Hospital Jakarta. Samples were taken consecutively until the amount of sample is met. Data were analyzed using unp aired T test. Results. There was a total of 46 subjects AMI patients in this study, ten subjects with depressive symptoms and 36 subjects without depressive symptoms. From the analysis, it was found that AMI patients with depressive symptoms had lower standard deviation normal to normal (SDNN) average (p=0.447), lower low frequency/high frequency (LF/HF) (p=0.323), and higher NLR average (p=0.438) than AMI patients without depressive symptom, although it was not statistically significant. Analysis showed that the mean value of SF36 total scores (p<0.001), physical function domain scores (p<0.001), energy domain scores (p<0.001), mental health domain scores (p<0.001), social function domain scores (p=0.028), bodily pain domain scores (p=0.002), and general health domain scores (p=0.002) were lower in AMI patients with depressive symptoms. Conclusion. AMI patients with depressive symptoms had lower SDNN, lower LF/HF, and higher NLR than AMI patients without depressive symptoms, although it was not statistically significant. AMI patients with depressive symptoms significantly have lower quality of life than AMI patients without depressive symptoms.
Co-Authors -, Shelly Abdulmuthalib Abdulmuthalib Aditya, Robby Nur Adli, Mizanul Agus Kosasih, Agus Ahani, Ardhi Rahman Ahmad Aulia Aldrat, Hendri Aldrat, Hendri Alida Harahap Andhika Rachman Andy William Andy William Antarianto, Radiana Dhewayani Ardian Saputra, Ardian Aru W Sudoyo Ary H Reksodiputro, Ary H Asrinda, Indria Atmakusumah, Tubagus Djumhana Auda Aziz, Auda Barasila, Atikah Chalida C. Martin Rumende, C. Martin Chyntia Olivia Maurine Jasirwan, Chyntia Olivia Maurine Deby Deby Djumhana Atmakusumah, Djumhana E. Mudjaddid A. Siswanto Deddy N.W.Achadiono Hamzah Shatri Edy Rizal Wahyudi Em Yunir, Em Endang Hardjolukito Endang Hardjolukito Endang Susalit Endang Susalit Filbert Jayalie, Vito Harahap, Agnes S. Harryanto Reksodiputro Harryanto Reksodiputro, Harryanto Hayatun Nufus Hayatun Nufus HENDRI ALDRAT Idrus Alwi Ika Prasetya Wijaya INDRAYANI, LENNY Jonlean, Reganedgary Leonard Nainggolan Lia Damayanti Lim Weng Kong, Lim Weng Linda Armelia Linda Armelia Linda Lison, Linda Luhuna, Muslimah Lyana Lyana, Lyana Maksum Radji Maksum Radji Marthino Robinson Marthino Robinson Maruhum B.H. Marbun Maruhum Bonar HM, Maruhum Bonar Merry Wintery, Merry Muchtaruddin Mansyur Muhadi Muhadi, Muhadi Murdani Abdullah Ni Ken Ritchie, Ni Ken Noorwati Sutandyo Nur Aditya, Robby Nurjati Chaeranie Siregar, Nurjati Chaeranie Oktarina, Caroline Ong Choon Kiat, Ong Choon Pawitan , Jeanne Adiwinata Purwoko, Reza Yuridian R.R., Aditia Rahmat Cahyanur Rahmat Cahyanur Rahmat Cahyanur Ralph Girson Gunarsa Rianto Setiabudy Ricci Steven, Ricci Rooshoeroe, A. G. Rudi Putranto Shelly - Soejono, C. H. Sri Inggriani, Sri Sukamto Koesnoe Tandarto, Kevin Teguh Santoso Tenggara, Jeffry Bela The Bin Tean, The Bin Tubagus Djumhana Atmakusumah Victor, Hildebrand Hanoch Vito Filbert Jayalie Vivian Soetikno Wijaya, Indra YAHDIANA HARAHAP Yahdiana Harahap